Prothena Stock Price, News & Analysis

Prothena Corporation plc (NASDAQ:PRTA) announced the hiring of two new employees, granting them options to purchase a total of 140,000 ordinary shares at an exercise price of $70.74. This price reflects the closing trading price on October 1, 2021. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over the following three years. This grant is part of Prothena's 2020 Employment Inducement Incentive Plan, approved by the board under Nasdaq guidelines.

Prothena Corporation (NASDAQ:PRTA) announced key executive changes aimed at bolstering its transition to a fully integrated biotechnology company targeting rare diseases. Tran B. Nguyen has been appointed Chief Strategy Officer while continuing his role as Chief Financial Officer. Brandon Smith steps in as Chief Operating Officer. These roles focus on enhancing Prothena's long-term growth strategy, operational capabilities, and pipeline development, aiding in its mission to commercialize novel therapeutics for conditions like AL amyloidosis and Alzheimer’s disease.

Prothena Corporation plc (NASDAQ:PRTA) announced the approval of a stock option grant to a new employee, allowing the purchase of 75,000 ordinary shares at an exercise price of $69.88. This is based on the closing trading price from September 1, 2021. The option will vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years. This grant aligns with Prothena's 2020 Employment Inducement Incentive Plan.

Prothena Corporation plc (NASDAQ:PRTA) announced participation in key investor conferences in September 2021, showcasing its commitment to addressing neurodegenerative diseases. Key events include Citi’s 16th Annual BioPharma Virtual Conference on September 8, featuring a fireside chat at 9:45 AM ET and a panel discussion at 11:35 AM ET. Additionally, the company will present at H.C. Wainwright's 23rd Annual Global Investment Conference on September 13 and the Cantor Global Healthcare Conference on September 27. Webcasts of these events will be available live and subsequently for 90 days on Prothena's website.

Prothena Corporation (NASDAQ:PRTA) reported a net income of $27.6 million for Q2 2021, a significant improvement from a net loss of $26.3 million in the same quarter last year. Revenue for Q2 reached $60.1 million, up from $0.2 million in Q2 2020, primarily driven by collaboration payments. The company announced multiple strategic collaborations, achieving over $200 million in milestone payments in 2021. Prothena anticipates a strong cash position of approximately $491 million by year-end, up from prior guidance of $316 million. Upcoming milestones include key clinical data presentations.

DUBLIN, Ireland, July 29, 2021 – Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first half of 2021 financial results on August 5, 2021, after U.S. market close. The company, known for its investigational therapeutics targeting protein dysregulation associated with rare peripheral amyloid and neurodegenerative diseases, will not hold a conference call for this release. Prothena aims to advance its pipeline, which includes treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases.

Prothena Corporation (NASDAQ:PRTA) presented promising data on its Alzheimer’s disease programs at the Alzheimer’s Association International Conference 2021. Highlights include the late-breaking poster on PRX012, demonstrating effective clearance of Aβ plaque in brain tissue, and a dual Aβ-tau vaccine that generates antibodies to target both amyloid and tau pathologies. PRX012 is noted for its high potency and potential for subcutaneous administration, promising improved patient compliance. The Investigational New Drug Application for PRX012 is anticipated in Q1 2022, enhancing Prothena's robust Alzheimer’s portfolio.

Dublin, Ireland, July 20, 2021 - Prothena Corporation plc (NASDAQ:PRTA) announced it will present preclinical data on its Alzheimer’s disease programs at the Alzheimer’s Association International Conference 2021 (July 26-30). The presentations will cover PRX012, a next-generation anti-amyloid beta antibody, and a dual Aβ-tau vaccine. PRX012 aims for improved efficacy and safety, with an IND expected in Q1 2022. The dual vaccine is designed to tackle both Aβ plaques and tau tangles, presenting significant therapeutic potential in addressing Alzheimer's, which currently affects over 5.8 million Americans.

Prothena Corporation and Novo Nordisk announced a definitive agreement for Novo Nordisk to acquire Prothena's clinical stage antibody, PRX004, aimed at treating ATTR cardiomyopathy. This deal includes milestone payments totaling up to $1.2 billion, with $100 million in upfront payments. PRX004, which has completed Phase 1 studies, is designed to deplete amyloid deposits linked to this rare heart disease. Novo Nordisk will focus on advancing PRX004 to address unmet medical needs in cardiac patients.